Overdosing tourists in vacation hotspot are straining local health system
A quarter of the ambulance emergencies are linked to large leisure centers, Spanish publication elDiaro.es reported.
The Works Council of the Union of Healthcare Technicians (WCUHT) told the outlet most of the calls are due to drugs or alcohol incidents at clubs involving foreign tourists — leaving ambulance technicians strained.
"The situation is entrenched because the population increases, leisure centers increase, and instead of moving forward we go backward," said union president José Manuel Maroto.
In 2024, about 3.28 million people visited Ibiza, while there were 3.38 visitors the year prior, according to the Ibiza Preservation.
"Serving tourists from nightclubs saturates the service and harms other emergencies on the island, which have to endure delays in ambulances," said Maroto.
A European Psychiatry study published by Cambridge University Press analyzed drug-related fatalities in Ibiza from 2010 to 2016.
The study found that MDMA and cocaine were the most commonly used substances, with the number of fatalities per year "steadily increasing."
Party promoter Wayne Anthony told Sky News last year he does not think the drug problem in Ibiza will be stopped.
"When you have these movements that are driven by music, that are driven by art, that are driven by fashion and drugs are a part of it, whatever you put up, whatever boundaries, whatever laws, I don't think you're going to be able to stop it," said Wayne.
He arrived on the island in 1988, noting that "what Ibiza represented was this beautiful, hot island, which was visually stunning and we knew you could party there quite legally."
The Center for Public Health researchers at Liverpool John Moores University published a 2014 study on the behavior of young British tourists between the ages of 16 and 35.
Of those surveyed, 85.3% reported using illicit drugs — while 54.1% smoked tobacco.
The WCUHT is calling for clubs to work with their own private ambulance services.
"Clubs are obliged to have a health service with nurses and even emergency technicians, but they are not forced to hire an ambulance service, and this ends up becoming a public system," said Maroto.
He added, "We all pay for ambulances to these companies that make billions. It is unaffordable."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
30 minutes ago
- Forbes
AI in Healthcare & Medical Hiring: The Front Lines
Aaron Dhaliwal, CEO, avua. As the CEO of avua, an AI-powered hiring platform supporting clients across North America, Europe and the Middle East, I've seen firsthand how artificial intelligence is revolutionizing the way healthcare talent is recruited, matched and retained. While AI is transforming patient care, diagnostics and drug discovery, what often gets overlooked is how profoundly it's also transforming healthcare hiring. We work across six sectors, including healthcare and medical, two of our fastest-moving industries. From nurses and pharmacists to clinical researchers and telehealth coordinators, demand is soaring and AI is now at the core of how we identify talent, assess skills and deliver faster, smarter matches for employers. Here are five ways AI is reshaping healthcare in 2025, through the lens of hiring, recruitment and workforce planning. 1. Drug Discovery Acceleration, Demand For AI-Literate Researchers AI is transforming drug discovery, cutting R&D timelines and reducing costs by analyzing enormous datasets in record time. But this speed creates new hiring challenges. Pharmaceutical companies now need biomedical researchers, data scientists and regulatory experts who understand platforms like AlphaFold, IBM Watson or BenchSci. We've seen a surge in pharma job posts that require hybrid skill sets, including biology, chemistry and AI fluency. Recruiters are now screening for candidates who can translate between science and machine learning. For Job Seekers: Update your CV with keywords like "AI in drug development," "clinical trial analytics" and "bioinformatics platforms." 2. Personalized Care Is Creating New Clinical Roles Healthcare is moving from reactive to proactive, and AI is powering that shift. Predictive analytics help identify patients at risk before symptoms emerge. But implementing these systems requires clinicians, care coordinators and analysts who can work with AI tools to create tailored care plans. Hospitals are looking to fill roles like AI-assisted care planners and digital health strategists, positions that barely existed two years ago. For Employers: Hiring managers need to rethink role requirements. Soft skills like empathy still matter, but digital and AI literacy are fast becoming nonnegotiable. 3. Clinical Trial Automation Is Creating Demand For AI-Enabled Coordinators Running clinical trials used to take years. Now AI can identify eligible participants, monitor data in real time and automate reporting. But someone still needs to run the show. We're seeing a spike in demand for clinical trial managers, compliance officers and site liaisons who can integrate with AI platforms like Medidata or TriNetX. For Job Seekers: Emphasize adaptability. Candidates who demonstrate quick learning of new tech tools, even outside healthcare, are outperforming traditional résumés. 4. AI Diagnostics Are Reshaping Radiology And Imaging Recruitment AI is now analyzing imaging scans faster and with fewer errors than human radiologists alone. But this doesn't replace people; it reshapes the role. Radiologists, technicians and imaging analysts are increasingly expected to work with AI systems, not in parallel. Recruiters are now looking for candidates who understand both clinical workflow and machine learning tools, often a rare combination. Our Platform Insight: Roles mentioning "AI in diagnostics" on our platform have grown 54% year over year. We now suggest employers include "AI integration experience preferred" in their job descriptions to attract the right profiles. 5. Telemedicine And AI: The Rise Of Digital-First Healthcare Roles Since the pandemic, telemedicine has become a staple of care, and in 2025, it's evolved. AI chatbots now triage basic cases, virtual assistants schedule visits and NLP tools handle documentation. As a result, employers are hiring for telehealth support, remote care managers and digital experience specialists at scale. These jobs aren't just clinical; they sit at the intersection of tech support, UX and patient engagement. Soft skills and tech fluency are key. For Job Seekers: Using keywords like "telehealth," "virtual care platforms" and "AI triage systems" is now a must to get noticed. Final Thought: Hiring For The Future Of Care AI isn't just changing healthcare; it's redefining who works in it, how they're hired and what employers should be looking for. The smartest organizations in 2025 aren't just adopting AI in their operations; they're using it to build better teams, faster. Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?
Yahoo
44 minutes ago
- Yahoo
Novo Nordisk (NVO) Gets Downgraded to Neutral from Buy at UBS
Novo Nordisk A/S (NYSE:NVO) is one of the top NYSE stocks with the highest upside potential. On August 5, UBS downgraded Novo Nordisk A/S (NYSE:NVO) to Neutral from Buy, bringing the price target down to DKK 340 from DKK 600. An elderly couple receiving insulin from a pharmacist, representing healthcare company's successful pharmaceutical products. The firm told investors in a research note that it sees 'challenging times' for Novo Nordisk A/S (NYSE:NVO), with its analysis showing that the US compounding of weight loss drugs is 'here to stay.' UBS added that this brings an uncertain outlook for Novo Nordisk A/S' (NYSE:NVO) Wegovy. Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products. While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Medscape
2 hours ago
- Medscape
Arboviruses: What Clinicians Need to Know
Europe is experiencing increasing prevalence of arbovirus diseases — those transmitted by arthropod vectors such as mosquitoes, ticks, or sand flies. These diseases, including dengue, chikungunya, and Zika, have traditionally been endemic to the tropical and subtropical regions of South America, the Caribbean, Africa, and Asia. Their frequency and scale have increased globally in the past two decades, and the geographic range of transmission has expanded into areas previously unaffected, including non-endemic regions in Europe. While most cases are imported, mosquito species and ticks are establishing themselves further northwards and westwards in Europe. According to the European Centre for Disease Prevention and Control (ECDC), between 2021 and 2024, the number of autochthonous (locally acquired) dengue outbreaks and cases increased considerably, and chikungunya and Zika infections have also now been reported in Mediterranean regions. Arbovirus Diseases Becoming More Common Tamás Bakonyi, ECDC principal expert on vector-borne and zoonotic diseases, told Medscape Medical News that arbovirus diseases have become more common in Europe due to a combination of environmental, biological, and societal factors. Climate conditions can change the environment in which infectious diseases thrive, contributing to their increase and impact, he said. Rising temperatures, milder winters, more frequent extreme weather events, and changing rainfall patterns may create more favorable conditions for the transmission of several vector-, food-, and waterborne diseases. 'Vector-borne diseases like dengue, chikungunya virus disease, West Nile virus infections, Lyme borreliosis, and tick-borne encephalitis are particularly sensitive to changes in temperature, humidity, and rainfall,' he explained. Warmer temperatures increase mosquito and tick survival and shorten pathogen incubation times, which in turn accelerates disease transmission cycles. Most Cases Imported International travel has led to the importation of arboviruses from endemic regions to Europe, Bakonyi said. This underlies most reported arbovirus infections in Europe but may spark local outbreaks. The ECDC collects data on imported cases on an annual basis. Its latest interactive surveillance atlas, for the year 2023, showed across the EU: Dengue: 5027 travel-associated cases vs 129 locally acquired cases. Chikungunya: 320 imported cases including in Spain (191), Germany (44), and France (39), with no reported locally acquired cases. Zika virus infection: 79 travel-associated cases with none locally acquired. In addition, the ECDC collects seasonal data over the summer on locally acquired cases of various arboviral diseases. Its latest communicable disease threats surveillance for the week ending August 01, 2025, showed: Locally acquired dengue in three European countries in 2025 so far: France (6, including 2 new cases since the previous week), Italy (3), and Portugal (2 in Madeira). Locally acquired chikungunya in France (49) and Italy (2) so far during 2025. Up to 30 July, Crimean-Congo hemorrhagic fever cases were reported in Greece (2) and Spain (2). Up to 30 July, human cases of West Nile virus infection were reported in Bulgaria, France, Greece, Italy, and Romania. Be Alert for Symptoms Clinicians across Europe this summer should be on the alert for symptoms of arbovirus infections, both mosquito-borne and tick-borne diseases, Bakonyi advised. Dengue — Most cases are imported by travelers returning to the EU from endemic areas, but these may generate local, mosquito-borne transmission in areas with competent vectors and supportive climatic/weather conditions. Transmission is primarily by Aedes aegypti globally and Aedes albopictus in Europe, where the species is increasingly frequent. Symptoms include an acute, high fever, occasionally progressing to hemorrhagic fever, with headache, myalgia, arthralgia, and a maculopapular rash. Up to 5% of cases can be severe, with increased vascular permeability that can lead to life-threatening hypovolemic shock. Chikungunya — A notifiable disease at the EU level. Around a third of cases are asymptomatic; the remainder are characterized by sudden onset fever, chills, headache, myalgia, nausea, photophobia, incapacitating joint pain, and petechial or maculopapular rash. Recovery may take months but typically occurs within 10 days and gives lifelong immunity. Zika — Generally asymptomatic, but may cause mild fever, arthralgia, and fatigue, with a maculopapular rash, conjunctivitis, myalgia, and headache. It is usually short (2-7 days) and self-limiting, but infection during pregnancy may lead to congenital central nervous system malformations such as microcephaly, with a raised risk for fetal loss. West Nile fever — About 80% of infections are asymptomatic but may cause fever, headache, malaise, myalgia, fatigue, and eye pain, sometimes with a rash. Some 1%-10% of cases may be severe, especially among older people. Most cases in humans occur between July and September, when mosquitoes are active. Diagnosis More Difficult Diagnosis should be on the basis of clinical presentation and epidemiologic context, as well as laboratory tests, which vary by disease, Bakonyi said. Testing has become more difficult recently due to the global expansion of arboviruses, leading to antibodies that cross-react on serological assays. As for treatment, Bakonyi recommended referring to the World Health Organization (WHO), which issued its first global arbovirus guidelines in July. These also point to the difficulty in distinguishing between arboviral infections because early symptoms often overlap. Treatment Largely Symptomatic Treatment is largely symptomatic in mild infections. With suspected or confirmed nonsevere dengue, chikungunya, Zika, or yellow fever, the WHO recommends oral rehydration, with paracetamol or dipyrone for managing pain and fever. Corticosteroids are not recommended in nonsevere infections, and nonsteroidal anti-inflammatory drugs should be avoided in all cases. For hospitalized patients with suspected or confirmed severe arboviral disease, the WHO recommends: Prefer crystalloid fluids over colloids for intravenous (IV) rehydration. Use capillary refill time and serum lactate levels to guide decisions on IV fluid management, with a passive leg raise test for patients in shock. Avoid systemic corticosteroids and immunoglobulins. Avoid prophylactic platelet transfusions in patients with platelet counts < 50,000/μL unless there is active bleeding.
